Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial.

The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA^® (pembrolizumab).

Read more at globenewswire.com